Felbamate

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Felbamate

Examples of brand names: Taloxa [DE]

ATC code: N03AX10

Main use (for orientation): Severe epilepsy

Documented research summary

CL20: positive association between CBD dose and felbamate concentration in an open-label cohort. No reliable fixed percentage increase or controlled human drug–drug interaction identified.

Uncertainties and limitations

Liver warnings for both medicines provide a reason for caution, not separately proven synergistic liver risk.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0052

Type of result: Positive finding / indication

Observation: Serum concentration ↑; p=0.0012.

Mechanism: Mechanism uncertain

Study type: Observational study

Context studied: n=7; overall.

Clinical interpretation: Clinical significance unclear

Limitations and uncertainties: Association based on unadjusted multiple tests. Table 2: p=0.0012; results text: p=0.0013 (internal discrepancy in the source).

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[CA_L_D0055] FELBATOL (FELBAMATE) TABLET FELBATOL (FELBAMATE) SUSPENSION [VIATRIS SPECIALTY LLC]

Original source / bibliographic reference

Authors: Viatris Specialty LLC

Year: 2025

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility